Detalhe da pesquisa
1.
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience.
Ann Oncol
; 20(1): 27-33, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18695026